سعر شورسالين 300مجم 30 قرص 2026

Oxcarbazepine 300 mg film-coated tablets, pack of 30 (3 strips); antiepileptic (Shorsalin, Global Napi Pharmaceuticals, Egypt).

• Monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Monotherapy of partial-onset seizures in pediatric patients aged 4 years and above, and adjunctive therapy in pediatric patients aged 2 years and above.Population: Children 2 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions: dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, headache, nystagmus, tremor and abnormal gait.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hyponatremia: clinically significant hyponatremia (sodium below 125 mmol/L) can develop, usually in the first 3 months but sometimes after more than a year; symptomatic hyponatremia and SIADH have been reported.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Anaphylaxis and angioedema (larynx, glottis, lips, eyelids) have been reported after the first or later doses; discontinue and do not rechallenge.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• About 25-30% of patients with hypersensitivity to carbamazepine will experience hypersensitivity to oxcarbazepine; use in such patients only if the potential benefit justifies the risk.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• PhenytoinPhenytoin levels increase with oxcarbazepine doses above 1200 mg/day; monitor phenytoin plasma levels during titration and a phenytoin dose decrease may be required.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 and/or UGT inducers (rifampin, carbamazepine, phenytoin, phenobarbital)Decrease plasma levels of the active metabolite MHD by 25-49%; monitor MHD levels during titration and adjust the oxcarbazepine dose as needed.DailyMed (U.S. National Library of Medicine)
• Hormonal contraceptives (ethinylestradiol, levonorgestrel)Oxcarbazepine decreases plasma concentrations of these hormones and may make hormonal contraceptives less effective; additional or alternative non-hormonal contraception is advised.DailyMed (U.S. National Library of Medicine)

• Pregnancy (US label): available human data have not demonstrated an increased prevalence of major congenital malformations with first-trimester exposure, but studies have important limitations; oxcarbazepine is structurally related to carbamazepine (a human teratogen) and caused developmental toxicity in animals. Seizure control should be maintained; patients should be encouraged to enrol in the NAAED Pregnancy Registry.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Lactation (US label): oxcarbazepine and its active metabolite MHD are present in human milk; effects on the breastfed infant and on milk production are unknown, so weigh the benefits of breastfeeding against the mother's clinical need.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Oxcarbazepine: Activity is exerted mainly through the 10-monohydroxy metabolite (MHD); oxcarbazepine and MHD block voltage-sensitive sodium channels, stabilising hyperexcited neural membranes and inhibiting repetitive neuronal firing (US Trileptal label section 12.1).